Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2585

Sort by

Sort Order Select

Journal Articles

How I treat pediatric acute myeloid leukemia

Jeffrey E. Rubnitz, Gertjan J. L. Kaspers

Blood (2021) 138 (12): 1009–1018.

https://doi.org/10.1182/blood.2021011694

Published: 2021

Journal Articles

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

Semjon Willier, Paula Rothämel, Maximilian Hastreiter, Jonas Wilhelm, Dana Stenger, Franziska Blaeschke, Meino Rohlfs, Theresa Kaeuferle, Irene Schmid, Michael H. Albert, Vera Binder, Marion Subklewe, Christoph Klein, Tobias Feuchtinger

Blood (2021) 137 (8): 1037–1049.

https://doi.org/10.1182/blood.2020006921

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Blood (2021) 137 (6): 751–762.

https://doi.org/10.1182/blood.2020007732

Published: 2021

Includes: Supplemental data

Journal Articles

Epigenetic reprogramming sensitizes immunologically silent EBV + lymphomas to virus-directed immunotherapy

Tanner Dalton, Ekaterina Doubrovina, Dmitry Pankov, Raymond Reynolds, Hanna Scholze, Annamalai Selvakumar, Teresa Vizconde, Bhumesh Savalia, Vadim Dyomin, Christoph Weigel, Christopher C. Oakes, Alicia Alonso, Olivier Elemento, Heng Pan, Jude M. Phillip, Richard J. O’Reilly, Benjamin E. Gewurz, Ethel Cesarman, Lisa Giulino-Roth

Blood (2020) 135 (21): 1870–1881.

https://doi.org/10.1182/blood.2019004126

Published: 2020

Includes: Supplemental data

Journal Articles

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Jordan Gauthier, Alexandre V. Hirayama, Janaki Purushe, Kevin A. Hay, James Lymp, Daniel H. Li, Cecilia C. S. Yeung, Alyssa Sheih, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Tinh-Doan Phi, Rachel N. Steinmetz, Mazyar Shadman, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2020) 135 (19): 1650–1660.

https://doi.org/10.1182/blood.2019002936

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss, Stephen J. Forman

Blood (2020) 135 (11): 804–813.

https://doi.org/10.1182/blood.2019002132

Published: 2020

Journal Articles

Virus-specific T-cell therapies for patients with primary immune deficiency

Michael D. Keller, Catherine M. Bollard

Blood (2020) 135 (9): 620–628.

https://doi.org/10.1182/blood.2019000924

Published: 2020

Journal Articles

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

Kendall H Sullivan, PharmD, Michael Toscani, PharmD, Tayla Poretta, PharmD, Ciera Patzke, PharmD, BCOP, Thushara Korattyil, PharmD, Denalee O'Malley, PhD MSW, Victor Gonzalez, MA, MS, Joseph Barone, PharmD, Andrew M. Evens, DO,MSc

Blood (2019) 134 (Supplement_1): 2134.

https://doi.org/10.1182/blood-2019-123459

Published: 2019

Journal Articles

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Anita J Kumar, MDMS, Rachel Murphy-Banks, MA, Ruth Ann Weidner, MBA, MRP, Susan K Parsons, MD MRP

Blood (2019) 134 (Supplement_1): 2137.

https://doi.org/10.1182/blood-2019-124481

Published: 2019

Journal Articles

Control of Hypercytokinemia in Critically Ill Epstein-Barr Virus Related Hemophagocytic Lymphohistiocytosis with Plasma Exchange and Continuous Renal Replacement Therapy

Chengshuang Huang, Pei Huang, PhD, Xueqin Jiang, Hongbo Xu, Jian Lu, Runmei Tian, Ping Zhu, MD, Yan Chen, MD

Blood (2019) 134 (Supplement_1): 2335.

https://doi.org/10.1182/blood-2019-122529

Published: 2019

Journal Articles

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Hisham Abdel-Azim, Christopher C. Dvorak, MD, Nancy Bunin, MD, Mark C. Walters, MD, Julie-An Talano, MD, Eric Jon Anderson, MD, Jemily Malvar, MS, May Al Jassani, Sonali Chaudhury, MBBS,MD, Mitchell S Cairo, MD, Carrie Kitko, MD, Allison P. Jacob, Dimitri S. Monos, PhD, Leung Wing, MD PhD, Michael A. Pulsipher, MD

Blood (2019) 134 (Supplement_1): 4624.

https://doi.org/10.1182/blood-2019-131706

Published: 2019

Journal Articles

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Ashley E. Rosko, MD, Sarah A Wall, MD, Robert A Baiocchi, MD PhD, Don M. Benson, Jr., MD PhD, Jonathan E. Brammer, MD, John C. Byrd, MD, Yvonne A. Efebera, MD MPH, Kami J. Maddocks, MD, Kerry A. Rogers, MD, Carolyn Presley, MD, Desiree Jones, Ying Huang, MS, MA, Michelle Naughton, PhD MPH

Blood (2019) 134 (Supplement_1): 4776.

https://doi.org/10.1182/blood-2019-130531

Published: 2019

Journal Articles

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

Jason G Underwood, PhD BA, Jenny L. Smith, MSc, MD, Lindsey F. Call, B.A., Elizabeth Tseng, PhD, Tiffany A. Hylkema, BS, Rhonda E. Ries, MA, Amanda R. Leonti, MS, Jason E. Farrar, MD, Timothy Junius Triche, Jr., PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 4658.

https://doi.org/10.1182/blood-2019-131508

Published: 2019

Journal Articles

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

Srividya Swaminathan, PhD, Line Dam Heftdal, MD, Daniel Liefwalker, PhD, Renumathy Dhanasekaran, MD, Anja Deutzmann, PhD, Crista Horton, BS, Adriane Mosley, BS, Mariola Liebersbach, BS, Andrew Gentles, PhD, Holden T. Maecker, PhD, Dean Felsher, MD PhD

Blood (2019) 134 (Supplement_1): 730.

https://doi.org/10.1182/blood-2019-122607

Published: 2019

Journal Articles

Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders

Luis E Malpica Castillo, MD, Shannon Palmer, MS, Anqi Zhu, MS, Allison Deal, MS, Sheh-Li Chen, PharmD, Stephan Moll, MD

Blood (2019) 134 (Supplement_1): 792.

https://doi.org/10.1182/blood-2019-121340

Published: 2019

Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski, MD, Zhen-Huan Hu, MPH, Yiyun Zhang, PhD, Manali Kamdar, MD, Monalisa Ghosh, Premal Lulla, MBBS, Joshua Sasine, MD PhD, Miguel-Angel Perales, MD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Margit Jeschke, PhD, Lan Yi, PhD, Raghav Chawla, MD PhD, Lida Pacaud, Mary M. Horowitz, Eric Bleickardt, MD, Marcelo C. Pasquini, MDMS

Blood (2019) 134 (Supplement_1): 766.

https://doi.org/10.1182/blood-2019-130983

Published: 2019

Journal Articles

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Naomi Michels, BSc, Judith M. Boer, PhD, Marta Lopez-Yurda, PhD, Hester A. De Groot-Kruseman, PhD, Vincent van der Velden, PhD, Anthony V. Moorman, Amir Enshaei, PhD, Ajay Vora, Rosemary Sutton, BSc MSc PhD, Toby Trahair, PhD, Luciano Dalla-Pozza, MBBS FRACP, Rob Pieters, MDPhDMSc, Michel C Zwaan, MD PhD, Monique L. Den Boer, PhD

Blood (2019) 134 (Supplement_1): 827.

https://doi.org/10.1182/blood-2019-124290

Published: 2019

Journal Articles

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Pablo Domizi, PhD, Astraea Jager, BS, Jolanda Sarno, PhD, Charles G. Mullighan, MBBS, MD, Stephan Grupp, MD PhD, Elena Sotillo, PhD, David M. Barrett, Kara L. Davis, DO

Blood (2019) 134 (Supplement_1): 749.

https://doi.org/10.1182/blood-2019-128883

Published: 2019

Journal Articles

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Michael Leukam, MDMS, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Riyue Bao, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 924.

https://doi.org/10.1182/blood-2019-131562

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I treat pediatric acute myeloid leukemia

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

DARTs point the way forward in AML

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Epigenetic reprogramming sensitizes immunologically silent EBV + lymphomas to virus-directed immunotherapy

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Virus-specific T-cell therapies for patients with primary immune deficiency

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

Late Effects Are Important Considerations in Initial Hodgkin Lymphoma Treatment Decision-Making According to Survivors

Control of Hypercytokinemia in Critically Ill Epstein-Barr Virus Related Hemophagocytic Lymphohistiocytosis with Plasma Exchange and Continuous Renal Replacement Therapy

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only